Olatec Therapeutics

Olatec Therapeutics is a privately held biopharmaceutical company founded in 2003 that is leading the development of specific NLRP3 antagonists, which are the mediators of the innate inflammatory response. The company is focused on developing a platform of safe, oral NLRP3 antagonist therapeutics to address a wide range of acute and chronic inflammatory diseases, including arthritis, heart failure, asthma, Alzheimer’s disease, multiple sclerosis, type-2 diabetes, melanoma, and breast cancers, among others. Olatec's lead compound, dapansutrile (lab code: OLT1177®), selectively targets NLRP3 to inhibit the production of pro-inflammatory cytokines IL 1B and IL 18, thus showing promise in treating these conditions. The company's last investment, a grant investment, was secured on 10 March 2023 from the Michael J. Fox Foundation. Olatec's drug development team, with over 10 years of experience, has unparalleled expertise in inflammation and immunology and includes international thought leaders. Olatec operates in the United States and Europe, with offices in New York and the Netherlands. With its innovative approach and focus on addressing unmet medical needs in the field of inflammatory diseases, Olatec Therapeutics has the potential to make a significant impact in the Biopharma, Biotechnology, Health Care, and Pharmaceutical industries.